SCHEMBL21659263

SCHEMBL21659263

CNC(=O)CCCCCNC(=O)C1CCC(CN2C(=O)C=CC2=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
NAAA Q02083 1/20 0.39
TLR2 O60603 1/20 0.38
TLR1 Q15399 1/20 0.38
TTR P02766 1/20 0.37
IL2 P60568 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
LMNA P02545 4/20 0.36
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17739999 0.89 NAAA (0.48) SMN1; SMN2NAAALMNAGNAI3GNAO1
SCHEMBL19703683 0.89 SMN1; SMN2 (0.43) SMN1; SMN2NAAALMNAGNAI3GNAO1
SCHEMBL20936573 0.88 SMN1; SMN2 (0.42) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL23347014 0.87 SMN1; SMN2 (0.43) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL6849179 0.87 PTGS1 (0.47) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL19703588 0.86 CNR1 (0.38) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL19703687 0.86 SMN1; SMN2 (0.38) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL20936656 0.86 SMN1; SMN2 (0.40) NAMPTSMN1; SMN2NAAATTRIL2
SCHEMBL14872066 0.86 NAAA (0.55) SMN1; SMN2NAAALMNAGNAI3GNAO1
SCHEMBL2779228 0.86 NAAA (0.55) SMN1; SMN2NAAALMNAGNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2020-06-25 US disclosed
US-20200031798-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF ARS Pharmaceuticals, Inc. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031798-A1 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF TLR8, TLR3, TLR5 NAMPT 2331/4885SMN1; SMN2 2986/4885NAAA 552/4885
US-20200199247-A1 ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF LTK, TGFBR2, TNIK NAMPT 1668/4885SMN1; SMN2 4212/4885NAAA 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.